What diseases does Platinib target?

Platinib is a targeted anti-cancer drug mainly used to treat malignant tumors carrying RET gene fusions or mutations, especially non-small cell lung cancer and thyroid cancer. RETThe gene is a proto-oncogene. When fused or mutated, it can lead to abnormal cell proliferation and tumor formation. Platinib, as a tyrosine kinase inhibitor, inhibits the growth and spread of tumor cells by specifically blocking the activity of the protein encoded by the RET gene.

In non-small cell lung cancer, RET gene fusion or mutation is a relatively rare driver gene mutation, but the emergence of platinib has brought new treatment options to these patients. Clinical trial results show that platinib has a significant effect on patients with non-small cell lung cancer with RET gene fusion or mutation, and can effectively control tumor progression and prolong the survival of patients.

For patients with thyroid cancer, especially those who do not respond well to traditional treatments, platinib has also shown good therapeutic effects. Platinib blocks the growth signaling pathway of tumor cells by inhibiting the activity of the protein encoded by the RET gene, preventing tumor cells from continuing to proliferate and spread.

In addition, platinib also has certain safety and tolerability. Although some adverse reactions may occur during use, most patients are able to tolerate it and continue treatment. Doctors will develop a personalized medication plan based on the patient's specific conditions to maximize the efficacy of Platinib while reducing the occurrence of adverse reactions.

In general, platinib is a targeted therapy for malignant tumors carrying RET gene fusions or mutations, bringing new treatment hope and options to such patients.

xa0

Reference link:https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ponatinib